{"id":412654,"date":"2021-01-12T00:04:28","date_gmt":"2021-01-12T05:04:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412654"},"modified":"2021-01-12T00:04:28","modified_gmt":"2021-01-12T05:04:28","slug":"adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/","title":{"rendered":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health"},"content":{"rendered":"
\n

\n – Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma<\/em>\n <\/p>\n

SAN FRANCISCO, Calif. and SUZHOU, China, Jan. 12, 2021 (GLOBE NEWSWIRE) — Adagene, Inc., a platform-driven, clinical-stage biopharmaceutical company with precision antibody engineering, discovery and development capabilities, today announced the successful completion of its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). As a result of the collaboration, Adagene discovered antibodies that Dr. Child\u2019s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer in adults, according to Frost & Sullivan.<\/p>\n

Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of the human genome. A growing number of HERV genes and proteins have been found to be expressed in different cancers, and they might represent new targets for tumor immunotherapy.<\/p>\n

\u201cThe novel antibodies that were co-discovered and tested by Adagene and the National Heart, Lung, and Blood Institute have enabled us to potentially develop the first CAR-T cell therapy candidate targeting a human endogenous retrovirus expressed in the majority of clear cell kidney tumors,\u201d said Dr. Childs. \u201cThis is an encouraging development that builds on decades of research in our quest to find ways to adapt and enhance immune cells to target and kill even the most aggressive cancers. I look forward to the evaluation and hopefully the development of this novel CAR-T cell and other antibody-based therapies in clinical trials.\u201d<\/p>\n

The NIH will lead and be responsible for the manufacturing and clinical development of the CAR-T cell therapy candidate.<\/p>\n

\u201cAdagene is honored to have worked with Dr. Childs and his laboratory on this novel family of HERV as a potential target for tumor immunotherapy,\u201d said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. \u201cUsing our NEObody\u2122 technology, we identified novel antibodies against HERV expressed targets in renal cell carcinoma, which to our knowledge has never before been accomplished. We look forward to the advancement of the first-in-class CAR-T cell therapy Dr. Childs\u2019 laboratory has pioneered based on antibodies discovered at Adagene. In the meantime, Adagene continues to progress its pipeline of programs developed with NEObody\u2122 and SAFEbody\u2122 technologies, to address unmet medical needs.\u201d<\/p>\n

NEObody\u2122 is part of Adagene\u2019s Dynamic Precision Library (DPL) platform, which combines computational biology and synthetic biology to enable the selection of antibody candidates with novel epitopes, robust CMC profiles and desired safety and efficacy attributes for downstream development.<\/p>\n

\n About Adagene<\/strong>
\n
Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.<\/p>\n

\n Forward Looking Statements <\/strong>\n <\/p>\n

This article contains forward-looking statements that reflect our current expectations and views of future events, including but not limited to those regarding the therapeutic potential of and potential clinical development and commercialization plans for Adagene\u2019s pipeline candidates, its strategic and financial plans and expectations, as well as financial projections.<\/p>\n

In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cis\/are likely to,\u201d \u201cpotential,\u201d \u201ccontinue\u201d or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to: our goals and strategies; our future business development, financial conditions and results of operations; results of our clinical trials and preclinical studies; the expected collaboration between NIH and us; our expectations regarding our relationships with our business partners and our other stakeholders; competition in our industry; and relevant government policies and regulations relating to our industry.<\/p>\n

Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Management\u2019s expectations and, therefore, any forward-looking statements in this presentation could also be affected by risks and uncertainties relating to a number of other factors, many of which are beyond Adagene\u2019s control. All information in this article is as of the date hereof, and Adagene disclaims any obligation to update or revise such information unless required by law.<\/p>\n

\n Investors Contact<\/strong>
\n
Raymond Tam
Adagene
86-8777-3626
Raymond_tam@adagene.com<\/a>
business@adagene.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Annie Starr
6 Degrees
973-768-2170
astarr@6degreespr.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma SAN FRANCISCO, Calif. and SUZHOU, China, Jan. 12, 2021 (GLOBE NEWSWIRE) — Adagene, Inc., a platform-driven, clinical-stage biopharmaceutical company with precision antibody engineering, discovery and development capabilities, today announced the successful completion of its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). As a result of the collaboration, Adagene discovered antibodies that Dr. Child\u2019s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer … <\/p>\n

Continue reading “Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412654","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma SAN FRANCISCO, Calif. and SUZHOU, China, Jan. 12, 2021 (GLOBE NEWSWIRE) — Adagene, Inc., a platform-driven, clinical-stage biopharmaceutical company with precision antibody engineering, discovery and development capabilities, today announced the successful completion of its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). As a result of the collaboration, Adagene discovered antibodies that Dr. Child\u2019s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer … Continue reading "Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T05:04:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health\",\"datePublished\":\"2021-01-12T05:04:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/\"},\"wordCount\":857,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/\",\"name\":\"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==\",\"datePublished\":\"2021-01-12T05:04:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk","og_description":"– Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma SAN FRANCISCO, Calif. and SUZHOU, China, Jan. 12, 2021 (GLOBE NEWSWIRE) — Adagene, Inc., a platform-driven, clinical-stage biopharmaceutical company with precision antibody engineering, discovery and development capabilities, today announced the successful completion of its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). As a result of the collaboration, Adagene discovered antibodies that Dr. Child\u2019s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney cancer … Continue reading \"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T05:04:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health","datePublished":"2021-01-12T05:04:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/"},"wordCount":857,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/","name":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==","datePublished":"2021-01-12T05:04:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNDE5OSMzOTExOTM2IzUwMDA2OTk2Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-milestone-of-car-t-collaboration-with-the-national-heart-lung-and-blood-institute-at-the-national-institutes-of-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412654"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412654\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}